02:08 , Jul 26, 2017 |  BC Extra  |  Company News

Lilly stretches Olumiant timeline, updates cancer strategy

Eli Lilly and Co. (NYSE:LLY) reported 2Q17 earnings and said it would delay its plans to resubmit an NDA for Olumiant baricitinib beyond 2017. The company also said it would narrow its oncology focus to...
23:00 , Mar 2, 2017 |  BC Week In Review  |  Clinical News

Pemetrexed RTD regulatory update

FDA accepted an NDA from Eagle for pemetrexed RTD as monotherapy to treat locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and in combination with cisplatin to treat mesothelioma. The PDUFA date is...
22:20 , Jan 4, 2017 |  BC Week In Review  |  Clinical News

Pemetrexed RTD regulatory update

Eagle said it submitted an NDA to FDA for pemetrexed RTD to treat locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and mesothelioma in combination with cisplatin. The product is a ready-to-dilute, IV...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Eli Lilly sales and marketing update

The U.K.’s NICE issued final guidance recommending the use of Alimta pemetrexed from Eli Lilly as a maintenance treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose disease...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Company News

Eli Lilly sales and marketing update

The U.K.’s NICE issued final draft guidance recommending Alimta pemetrexed from Eli Lilly as a maintenance treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose disease has not...
07:00 , Jul 21, 2016 |  BC Extra  |  Company News

NICE now backs Alimta maintenance therapy

In a final draft guidance, the U.K.'s NICE recommended Alimta pemetrexed from Eli Lilly and Co. (NYSE:LLY) as a maintenance treatment for locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

Allergan, Eli Lilly cancer news

The U.K. High Court ruled that Eli Lilly’s Alimta pemetrexed vitamin dosing regimen patent would not be infringed by Allergan marketing pemetrexed salt formulations in the U.K., France, Italy and Spain with instructions to...
07:00 , Oct 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glycinamide ribonucleotide formyltransferase (GARFT); folate receptor 1 (FOLR1; FR-α); FOLR2 (FR-β); solute carrier family 46 folate transporter m

Cancer INDICATION: Cancer Mouse and cell studies identified an inhibitor of GARFT, FOLR1, FOLR2 and SLC46A1 that could help treat folate receptor-expressing cancers. Chemical synthesis and in vitro testing of pyrimidine antifolate thienoyl analogs identified a compound...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Company News

Allergan, Eli Lilly cancer news

The U.K. Court of Appeal ruled that Allergan’s pemetrexed salt formulations would indirectly infringe an Alimta pemetrexed vitamin dosing regimen patent. The patent covering vitamin dosing regimens of the antifolate that inhibits thymidylate...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

Alimta pemetrexed: Phase III final data

Alimta is approved in the U.S. and EU in combination with cisplatin for first-line treatment of non-squamous NSCLC, and for maintenance and second-line treatment of non-squamous NSCLC. The drug is also approved to treat malignant...